Physician

Austin Poole, MD

According to 2025 Medicare claims, Austin Poole, MD (NPI: 1053686253) practices hematology/oncology in the Boulder, CO market, with the plurality of this provider's patient population coming from Boulder, CO. This provider's primary affiliated billing organization is ROCKY MOUNTAIN CANCER CENTERS LLP (NPI: 1518941186; TIN: 841457488) and primary practice location at 80303-1385.

Poole's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 620 traditional Medicare patients, billed 135,352 HCPCS/CPT codes, and received $3,197,122 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,433 prescription claims across 314 beneficiaries totaling $4,718,277 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 12 claims. Open Payments data shows 3 records totaling $85. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $419,658 to $3,197,122. Similarly, Part D prescription costs have moved sharply higher in recent years, from $38,071 to $4,718,277. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	217	25,085	$419,658
2019	573	121,854	$1,834,863
2020	528	129,319	$1,607,234
2021	626	124,358	$1,792,758
2022	634	140,693	$2,349,049
2023	578	129,575	$2,435,400
2024	620	135,352	$3,197,122

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	42	101	$38,071
2016	35	62	$9,867
2017	28	56	$7,033
2018	59	164	$154,364
2019	150	854	$1,838,849
2020	165	1,205	$2,225,963
2021	218	1,566	$3,136,968
2022	233	1,735	$3,892,831
2023	250	1,816	$4,097,061
2024	314	2,433	$4,718,277

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	12	$127,367
2021	N/R	12	$128,316
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	12	$884

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	117	329	$103
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	126	459	$98
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	310	584	$66
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	91	184	$49
96375	Injection of additional new drug or substance into vein	87	331	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	32	889	$696,885
Revlimid	Lenalidomide	31	861	$576,439
Jakafi	Ruxolitinib Phosphate	32	960	$505,652
Nubeqa	Darolutamide	24	720	$351,269
Calquence	Acalabrutinib Maleate	21	630	$322,866

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	12	$884

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$85	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Austin Poole, MD?

Tedicare shows public-source Medicare data for Austin Poole, MD (NPI 1053686253), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Austin Poole, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Austin Poole, MD?

Austin Poole, MD is linked to ROCKY MOUNTAIN CANCER CENTERS LLP (billing NPI 1518941186) in the available physician profile data.

Does Austin Poole, MD have Open Payments data?

Austin Poole, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.